Vertex was only bidder for Crinetics in year's second-highest M&A premium

July 22, 2026 06:00 AM EDT DealsPharma Ver­tex was on­ly bid­der for Cri­net­ics in year's sec­ond-high­est M&A pre­mi­um Kyle LaHucik Biotech Correspondent To gain con­trol of Cri­net­ics Phar­ma­ceu­ti­cals, Ver­tex Phar­ma­ceu­ti­cals was will­ing to pay the sec­ond-high­est pre­mi­um so far in bio­phar­ma’s ban­ner year for M&A. And the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER